Showing 901-910 of 1614 results for "".
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- New Book Now Available: "Cataract Surgery: Advanced Techniques for Complex and Complicated Cases"https://modernod.com/news/new-book-now-available-cataract-surgery-advanced-techniques-for-complex-and-complicated-cases/2481018/Renowned ophthalmologists Jorge Alio, MD, PhD, FEBOphth; Buchard Dick, MD, PhD, FEBOS-CR; and Bob Osher, MD, have edited a new book titled "Cataract Surgery in Complex and Complicated Cases." It includes a large number of videos that aims to enrich the didactic value
- Experts Provide Update on Medicare Waivers and Other Regulatory Provisions During COVID-19https://modernod.com/news/experts-provide-update-on-medicare-waivers-and-other-regulatory-provisions-during-covid-19/2479527/In a recent episode of Ophthalmology Off the Grid, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, spoke with Allison Shuren, JD, MSN; Paul Rudolf, MD, JD; and Thomas Gustafson, PhD, to discuss a variety of regulatory topic
- Retina Specialists in US Hot Zones Report on How Offices, ORs Have Changed During COVID-19 Spreadhttps://modernod.com/news/retina-specialists-in-us-hot-zones-report-on-how-offices-ors-have-changed-during-covid-19-spread/2477521/New Retina Radio, Retina Today’s podcast, featured a conversation with three doctors from hotspots in the United States. John W. Kitchens, MD, moderated a conversation with George Williams, MD, from the Oakland University School of Medicine, outside of Detroit; Gwen Cousins, MD, from Ret
- VisionHQ Establishes Advisory Boardhttps://modernod.com/news/visionhq-establishes-advisory-board/2486441/VisionHQ, which provides in-house membership management and loyalty platform for eye care providers, has announced the formation of its Advisory Board. The move marks a strategic step forward in the company’s mission to help optometry practices boost patient retenti
- Nordic Pharma Announces European Launch of Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-announces-european-launch-of-lacrifill-canalicular-gel/2485691/Nordic Group, the parent company of Nordic Pharma, announced the European launch of Lacrifill, a novel therapy for the management of dry eye disease. Following CE mark approval in April 2025, Lacrifill is now available to healthcare professionals and patients acros
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has
- Bascom Palmer Eye Institute Tops U.S. News & World Report Rankings for 24th Year in a Rowhttps://modernod.com/news/bascom-palmer-eye-institute-tops-us-news-world-report-rankings-for-24th-year-in-a-row/2482911/For the 24th year, Bascom Palmer Eye Institute has been ranked the No. 1 ophthalmology hospital in the United States, according to the newly released 2025 U.S. News & World Report "Best Hospitals" rankings. This marks the 22nd consecutive year th
- Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RPhttps://modernod.com/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp/2482884/Nanoscope Therapeutics announced the initiation of a rolling submission of a biologics license application (BLA) to the FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa (RP). This marks a significant re
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo